Volume 131, Issue 3



January 18, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Insights into mechanisms of ferritin secretion. See the article by Truman-Rosentsvit et al.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia
The investigators demonstrate the clinical utility of a gene mutation classifier combined with minimal residual disease assessment in the risk stratification of pediatric patients with T-cell acute lymphoblastic leukemia.

Ferritin is secreted via 2 distinct nonclassical vesicular pathways
Serum ferritin is used as a clinical marker of iron stores, but the mechanism of ferritin secretion remains poorly understood. This work describes novel pathways for ferritin secretion directly relevant for understanding iron homeostasis.

Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
Whether ASXL1 mutations are loss-of-function, dominant negative, or gain-of-function mutations remains a point of controversy. The investigators present evidence of a new “gain-of-function” role of the ASXL1 oncogene in myeloid malignancies.

Platelets and vascular integrity: how platelets prevent bleeding in inflammation
This review provides a concise discussion covering the mechanisms of platelet-mediated prevention of inflammatory bleeding.

Prochemerin cleavage by factor XIa links coagulation and inflammation
This study reveals a novel link between coagulation and inflammation and shows that factor XIa can generate the active chemoattractant and adipokine chemerin from its inactive precursor, prochemerin.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
The authors present the final results of one of the largest randomized trials conducted with newly diagnosed transplant-ineligible patients with myeloma. They report that lenalidomide-dexamethasone confers a survival benefit over melphalan-prednisone-thalidomide, and they establish lenalidomide-dexamethasone as a new standard of care.


View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.